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Retinoids exert their biologic effects through two 
families of nuclear receptors, retinoic acid receptors 
(RARs) and retinoid X receptors (RXRs), which be-
long to the superfamily of steroid/thyroid hormone 
nuclear receptors. By using a subtraction hybridiza-
tion approach, we have identified a eDNA sequence 
TIG2 (Tazarotene-induced gene 2), whose expression 
is up-regulated by the treatment of skin raft cultures 
by an RAR /3/y-selective anti-psoriatic synthetic ret-
inoid tazarotene {AGN 190168/ethyl 6-[2-(4,4-di-
methylthiochroman-6-yl)-ethynyl] nicotinate}. The 
retinoid-mediated up-regulation in the expression of 
TIG2 was confirmed by Northern blot analysis. Upon 
sequencing, TIG2 was found to be a eDNA whose 
complete sequence was not in the GenBank and 
EMBL data bases. The TIG2 eDNA is 830 bp long and 
P harm acologic and physiologic retinoid signals in skin are transduced through two families of nuclear recep-tors, namely, retinoic acid receptors (RARa , {3, and y) and retinoid X receptors (RX R a, {3 , and y) (C hambon , 1994: Mangelsdorf et a/ , 1994; Boehm et al , 1995; 
Nagpal and C handraratna, 1996). RARs, which belong to the 
superfamily of steroid/thyroid/vitamin D 3 nuclear receptors, 
readily heterodimerize with RX.R.s in IJilro (for references see, 
Nagpal and Chandraratna, 1996) and function as such i11 LJiiJo 
(Nagpal et a/ , 1993). RARs are ligand-dependent transcription 
factors that activate the expression of retinoid-responsive genes by 
cooperative action of their activation functions, AF-1 (ligand-
independent activation function) , and .AF-2 (ligand-dependent 
activation fi.mction) (Nagpal et al, 1992, 1993) . R etinoids have been 
extensively used for the treatment of vatious nonmalignant (psori-
asis and acne), and malignant (squamous cell carcinoma, actinic 
keratoses, basal ceU carcinoma, and Kaposi's sarcoma) skin diseases, 
and th ey hold significant potential as a therapeutic modality in 
vat;ous epithelial cancers (Peck and DiGiovanna, 1994; Boehm et 
al, 1995; N agpal and C handraratna, 1996) . Despite their therapeu-
tic effi cacy in various dermatologic diseases, the mol ecular basis of 
retinoid action in skin is poorly understood. Various genes whose 
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encodes a putative protein product of 164 amino 
acids. TIG2 is neither expressed nor induced by taz-
arotene in primary keratinocyte and fibroblast cul-
tures. Thus, TIG2 is expressed and induced by taz-
arotene only when keratinocytes and fibroblasts form 
a tissue-like 3-dimensional structure. We further 
demonstrate that RAR-specific retinoids increase 
TIG2 mRNA levels. In contrast, neither RXR-specific 
retinoids nor 1,25-dihydroxyvitamin D 3 increased 
TIG2 levels. Finally, we demonstrate that TIG2 is 
expressed at high levels in nonlesional psoriatic skin 
but at lower levels in the psoriatic lesion and that its 
expression is up-regulated in psoriatic lesions after 
topical application of tazarotene. Kq words: vetinoic 
acid l'eceptovlpsoriasislsubtmctive l1ybYidiz atiou. J Invest 
Dermatol 109:91-95, 1997 
expression is induced i.n cell culture system s by retinoids have been 
described. Of these, cellular retinoic acid binding protein II 
(CR.ABPII) is the only marker whose expression is induced by 
retinoic acid (R.A) in normal skin (Elder et a/, 1993). In contrast, 
CR.ABPII expression is downregulated by RA in submet·ged kera-
tinocyte cultures (Elder and Cromie, 1993), and it is also overex-
pressed in psoriasis (Didietjean et a/, 1991), a hyper-proliferative 
and inflammatory condition of skin (Krueger and Duvic, 1994) that 
can be treated by retinoids (Esgleyes-Ribot et a!, 1994; Weinstein, 
1996). The increased levels of CR.ABPII i.n psodatic plaques 
indicates that it may not be a useful efficacy marker of retinoid 
action in psmiatic lesiom. In addition , several lines of evid en ce 
suggest that CR.ABPli fimctions to modulate retinoid action by 
sequestering RA away fi·om the nucleus ru1d by enhancing RA 
metabolism (Boylan and Gudas, 1991; Fiorella and Napoli, 1991). 
To further un.derstru1d the molecular m echanisms of retinoid 
therapeutic action in skin , we sought to identi fy genes whose 
expression is induced in a 3-dimensional skin culture system (skin 
rafts) by an anti-psoriatic synthetic retinoid, tazarotene (AGN 
190168) (Weinstein, 1996) . Since tazarotene is topically efFective in 
the treatm ent of psoriasis, studying its mechrulism of action would 
provide insight into how retinoids affect the disease. Recently, by 
using a subtractive hybridization approach in skin rafts , we identi-
fi.ed a novel gene, tazarotene-induced gene 1 (TIG l), whose 
expression was induced in skin rafts and psoriatic lesions by 
tazaroten e (Nagpal et a/ , 1996). With a similar strategy for identi-
fication of difFerentially expressed transcripts, we have now iden-
tified another novel gen e, tazarotene-induced gene 2 (TIG2) , 
whose expression is up-regulated by this anti -ps01;atic retinoid in 
skin rafts. Interestingly, unlike TIG1, TJG2 is not expressed in 
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2-dimensional cultures of keratinocytes and fibroblasts. The basal 
and retinoid-induced expression of TIG2 is observed only when 
keratinocytes and fibroblasts form a tissue-like structure as in skin 
rafts and psoriatic lesions. We also demonstrate that T IG2 is 
induced by RAR-specific but not significantly by RXR-specific 
retinoids and 1 ,25-dihydro:x:yvitamin D 3 . Finally, we demonstrate 
that TIG2 is expressed at high levels in nonlesional psoriatic skin 
but only at lower levels in the psoriatic lesion and that topical 
application of tazarotene to psoriatic plaques results in a rapid 
upregulation of TIG2 expression. 
MATEIUALS AND METHODS 
Skin Rafts and Primary Cultures of Keratinocytes and Fibroblasts 
Normal skin raft cultures (model ZK 1300, Advanced Tissue Sciences, San 
Diego, CA) are 3-di.mensional models of human skin tissues that have 
demnl, epidermal, and comified layers. T hese skin rafts were made by the 
manufacturer by seeding neonatal fibrob lasts (pooled from 10 donors) onto 
a nylon mesh, which gave rise to a dermal tissue. Keratinocytes seeded on 
top of the dennal tissue differentiated into multilayered epidermis consisting 
ofbasal, spinous, and granular layers and stratum cornew11. Primary cultures 
of foreskin keratinocytes and fibrob lasts were purchased (Cionetics, San 
Diego, CA). 
Subtractive Hybridization Skin raft cultures were either mock-treated 
or treated with the retinoid tazarotene (1 p.M) on days l and 3 and harvested 
on day 4 for total RNA preparation as described previously (Nagpal et al, 
1996). eDNA prepared from tazarotene-treated skin raft cultures was 
directionally cloned into Sali- Noti sites ofpSPORT-1 (Life Technologies, 
Gaithersburg, MD) and single-stranded DNA (ssDNA) was prepared from 
106 transformants as described previously (Li et al, 1994; Nagpal et al, 1996). 
Another directional eDNA library was constructed in Sail-Not! sites of 
pSPORT-2 (Life Technologies, Gaithersburg, MD), by using eDNA from 
mock-treated skin rafts, linearized with Sail and i11 vitro- transcribed in the 
presence ofbiot:in- 14-CTP as described (Li el al, 1994). pSPORT-1. ssDNA 
was blocked with a Noll-oligo primer 5'-GCGGCCGCCCT15-3' by incu-
bation at 70°C for 20 min with 600 p.M dTTP and Taq DNA polymerase. 
Poly(dA)-blocked ssDNA (600 ng) was hybridized with biot:inylated RNA 
(80 p.g) in 2 X hybridization buffer (80% formamide, 100 mM N-(2-
hydroxyethyl)piperazil)e-N' -(2-ethanesulfonic acid), pH 7 .5, 2 mM ethyl-
enediamine tetraacetic acid, 0.2')'(, sodium dodecyl sulfate) for 24 h at 42°C 
with shaking (200 rpm). The control experiment contained all the compo-
nents except biotinylated RNA. After hybridization, streptavidin (25 p.g) 
was added <md the 1nixture was incubated at .room temperature (5 min). 
Common ssDNA/RNA sequences were removed by phenol/chloroform 
extraction (five times), and unhybridized ssDNA was precipitated and 
electroporated into DH12S (Life Tecllllo.logies, Gaithersburg, MD) cells. 
Retinoids All-tra11s-retinoic acid (RA) and 1,25-dihydrox-yvitamin D 3 
were purchased (Sigma , St. Louis, MO, and Calbiochem, La Jolla , CA). 
Tazarotene {ethyl 6-[2-( 4,4-dimethylthiochroman-6-yl)-ethynyl) nicotinate) , 
SR 11217 {4-[1-(5,6, 7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-
methyl-1-propenyl]benzoic acid} and SR 11237 [2-(4-carboxyphenyl)-2-
(5 ,6, 7 ,8-tetrahydro-5 ,5,8,8-tetramethyl-2-naphthalenyl)-1 ,3-dioxolane] were 
synthesized in the Department of Chemistry, Retinoid Research, Allergan. 
Northern Blot Hybridization For northern blot hybridization, total 
RNA (10 (.Lg) was electrophoresed on 1% agarose-1.1 M formalde hyde 
gels, transferred to Nytran, and probed with labeled eDNA probes at 42°C 
for 18 h. The most stringent wash was at 65°C in 0.1 X SSPE (0.18 M NaCl, 
10 mM sodium phosphate, pH 7.4, l mM ethylenediamine tetraacctic 
acid)/1% sodium dodecyl sulfate for 30 min. 
In Situ Hybridization I11 situ hybridization was performed on paraffin-
embedded paraformaldehyde-ftxed sections by using Geni us kit (Boehr-
inger Mrumheim, Indiru1apolis, IN). Proteinase K (2 .5 (.Lg per ml) digestion 
was carried on for 30 min and hybridization with digoxigenin-labeled 
anti-sense probe (0 .4 ng per ml) was performed at 44°C. Nonspecific 
binding was blocked with normal sheep serum (2'V.,) , and specific binding 
was detected by incubation (3 h) with alkaline phosphatase-conjugated 
ant:i-digoxigenin antibody followed by a 4-h incubation with n.itrob lue 
tetrazolium substrate at 37°C. Sense probes were used in parallel as negative 
controls and showed no background staining. 
RESULTS 
Identification of a Novel Retinoid-Responsive Gene, TIG2, 
by Subtraction Hybridization Tazarotene (AGN 190168), an 
RAR{3/ ')'-selective retinoid, is topically effective in the treatment of 
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Figure 1. Identification of a tazarotene-induced eDNA clone. 
eDNA clone B1, obtained fi·om subtracted eDNA lib rary, was confirmed to 
be tazarotene-responsive by northern blot hybridization. Tota l RNA (10 
(.Lg) fi·om mock-treated or tazarotene-treated skin raft cultures was sub-
jected to northern blot hybridization. GAPDH and B1 sequences were 
detected with labeled eDNA probes. The northern blot signals, quantified 
in terms of total volume (an arbitrary unit) by Phosphorlmager (M.olecular 
Dynamics , Sunnyvale , CA), are also presented. T he overnight exposure of 
the blot in the Phosphorlmager screen is presented. The message level ofB 1 
eDNA clone was induced 4-fold after tazarotene treatment of skin raft 
cultures. 
psoriasis (Esgleyes-Ribot et al, 1994; Weinstein, 1996), a skin 
disease characterized by keratinocyte hyper-proliferation and infil-
tration of immnne cells into epidermis and dermis. To identify 
tazarotene- responsive genes in skin, we used a subtraction hybrid-
ization procedure (Li eta/, 1994; Nagpal eta/, 1996) to isolate 
differentially regulated genes from skin raft cultures. Differentially 
expressed genes in tazarotene-treated skin rafts, isolated after 
subtraction of common eDNA sequences between vehicle-treated 
and tazarotene-treated skin rafts, were analyzed by northern blot 
hybridization . The expression of one of the subtracted eDNA 
clones, B 1, was induced after tazarotene treatment of skin rafts (Fig 
1). The b lot was also probed with labeled G lyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (a housekeeping gene) eDNA 
to ensure that equal quantities of control and retinoid- treated RNA 
were used in the northern b lot ana lysis (Fig 1). Quantitation of the 
northern message showed a 4-fold increase in B1 expression after 
tazarotene treatrnent. Upon sequencing, Bl was found to be 830 bp 
in length, contained an open reading frame from 157 to 648 bp, and 
coded for a putative protein product of 164 amino acids (Fig 2) . 
The ATG (157-159 bp) protein initiation codon was confirmed by 
the presence of an in-frame stop codon (TGA) 12 bp upstream of 
the ATG codon (Fig 2A). It had a canonical poly(A) signal 
(5'-AATAAA-3') at bp 750 and a lo ng poly(A) tail starting at bp 
769 (Fig 2) . Homology search es from DNA (GenBank and EMBL) 
datab ases showed significant homology to a 176-bp mRNA se-
quence (GenBank accession number, L07329) isolated from retina l 
pigment epith elia l cells (Fig 3A). Further homology search es from 
protein (Swiss-Prot) database did not show identity to known 
protein sequen ces. W e therefore conclude that Bl is a novel eDNA 
sequence. Subsequently, anotl1er eDNA clone, B13, was identified 
from the same library as a tazarotene-induced gen e and upon 
sequencing was found to be identical to Bl. Because we have 
previously reported a tazarotene-induced gen e as TIGl, B1 will 
h ereafter be referred to as tazarotene-induced gene 2, or TIG2. A 
hydrophobic stretch of 20 am.ino acids in the N-terminal region of 
the protein (Fig 3B) indicated that the TIG2 p roduct might be a 
membrane- associated protein. TIG2 also contained putative 
signals for casein kinase II phosphorylation (amino acids 50-53 
and 54-57), myristylation (amino acids 16-21 and 29-34), and 
protein kinase C phosphorylation (amino acids 76-78). These 
putative motifs were identified by MacDNASIS PROSITE pro-
gram. T he consensus seq u ences used for searching phosphory-
lation sites were (S/T)- X-X- (D/E) and (S/T)-X-(R/K), respec-
tively, for casein kinase II and protein kinase C phosphorylation 
motifs (MacDNASIS). 
Interestingly, TIG2 was not up- regulated by tazarotene or RAin 
2-dimensional cu ltures ofkeratinocytes (Fig 4A) or fibroblasts (Fig 
VOL. 109, NO. 1 JULY 1997 
4B). GAPDH contro ls for RNAs are also shown in Fig 4A and B 
for keratinocytes and fibrob lasts, respectively. Also, TIG2 was 
expressed exclusively in the epidermis of nonlesional and lesional 
psoriatic skin and was up-regulated in psoriatic lesions by tazaro-
tene treatment (vide s11pra, Fig 5). These findings suggested two 
plausible reasons why TIG2 was not retinoid-inducible in kerati-
nocyte and fibroblast cultures: (i) the retinoid might induce a 
fibroblast-specific factor that then up-regulates TIG2 expression in 
keratinocytes or (ij) TIG2 mjght be expressed and induced in a 
retinoid-dependent manner only when keratinocytes and fibro-
blasts form a "tissue" structure as in skjn rafts and skin. To test the 
fu·st possibility, keratinocytes were treated with tazarotene in the 
presence of fibroblast-conditioned medium. These keratinocytes 
also exhibited neither basal nor tazarotene-induced expression of 
TlG2 (Fig 4C), therefore ruling out the possibility of a retinoid-
responsive fibroblast-specific factor in the induction ofTIG2. The 
GAPDH contro l for the keratinocytes grown in fibroblast- condi-
tioned medium is also shown (Fig 4C). 
TIG2 Responds to RAR but Not to RXR or Vitamin 0 3 
Receptor (VDR) Agonists Tazarotene (AGN 190168) acti-
vates gene expression only through RARs and not through RXH.s 
(Nagpal et al , 1995 , 1996). Further, AGN 190168 is RAR{3/'y-
selective and exhibits only weak transactivation through RARa 
(Nagpal et a/, 1995). In contrast, SR 11217 and SR 11237 are 
RXR-specific and do not activate gene expression through RARs 
(Lehmann et nl, 1992). 1 ,25-Dihydroxyvitamin 0 3 is a ligand for 
VDR and induces the expression of VDR-responsive genes 
through its cognate nuclear receptor. To determ.ine the receptor 
specificities of TIG2 expression, skjn rafts were treated with 
RA1~-specific (Tazarotene), RXI~-specific (SR11217 and 
61 120 
121~~~~~~ocr~~~~~~~~ 
1 M R R L L I P L 
181axcrorrn~xmxn~nx~ox~~~~XG~xa~~ 
8 A L W L G A V G V G V A E L T E A Q R R 
241 ~~CAC'J>,!>C.'CK.:c:cGO:C:cm:r:x;m:nx=:cAG 
28 G L Q V A L E E F H K H P P V Q W A F Q 
301 TAT1'1'GIGI\!D::I 
48 E T S V E S A V D T P F P A G I F V R L 
361~TIT~CIT~~~~COCDa~~~~~~~XO~mx~ 
68 E F K L Q Q T S C R K R D W K K P E C K 
180 
8 
240 
28 
300 
48 
360 
68 
420 
88 
421 m'CJ>DXCCAA~~~ 480 
88 V R P N G R K R K C L A C I K L G S E D 108 
481 ~'IGS'TC.'CACro:T~ 540 
108 K V L G R L V H C P I E T Q V L R E A E 128 
541 600 
128 E H Q E T Q C L R V Q R A G E D p H S F 148 
W1T 6W 
148 Y F P G Q F A F S K A L P R S • 163 
Figure 2. Nucleotide and putative protein sequence ofTIG2 (Bl). 
Bl eDNA clone was sequenced and analyzed by MacDNASIS (Hitachi, San 
Bruno, CA) program for open reading frames. Nucleotide and putative 
protein sequence of T!G2 as obtained from our subtracted eDNA library 
after sequencing two independent eDNA clones (B1 and B13) in both 
directions is shown. GenBank accession number, U77594. 
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Figure 3. Nucleotide homology and hydropathic profile of TIG2. 
The nucleotide and putative protein sequences of TIG2 were analyzed by 
MacDNASIS (Hitachi, San Bnmo, CA) program for nucleotide and protein 
homologies from GenBank, EMBL, and Swiss-Prot databases. (A) The 
homology (approximately 60%) between TIG2 a11d the partial eDNA clone 
L07329, of176 bp from retinal pigment epithc!illl cells, is shown . The upper 
strand represents the T IG2 eDNA forward sequence and the lower strand 
corresponds to the L07329 eD NA sequence. (B) Kytc-Doolittle hydropho-
bicity plot ofT!G2 showing hydrophobicity (y axis) <~ga.inst amino acids (x 
axis) is presented. l~egions of the protein greater than + 0.50 arc predicted 
to b<.: membrane-embedded (MacDNASIS) . 
SR11237), or VDR- speci.fic (1,25-dihydroJ~:yvitam.i.n 0 3 ) ligands. 
Only the RAR-specific ligand significantly induced TIG2 expres-
sion (Fig 4D), thus demonstrating tl1at the induction of TIG2 is 
mediated through RAR but not by RXR or VDR agonist-
dependent signal transduction patl1ways. 
Topical Application of Tazarotene (AGN 190168) Induces 
TIG2 Expression in Psoriatic Lesions To evaluate induction 
of TIG2 i11 JJ i JJo in psoriatic lesions, patients with long-standing 
plaque-type psoriasis were treated once daily with topical tazaro-
tene gel (0.1 %) tor up to 8 wk. Skju-punch biopsies were taken 
before the treatm.ent and after 3 and 14 d of tazarotene treatment. 
A biopsy was also taken fi·om the nonlesional skjn of the psoriatic 
patients before start of treatment. A typical i11 sifr,, hybddization 
using rugoxigenin-labeled TIG2 anti-sense RNA showed intense 
staining for TIG2 mRNA expression in the epidermis of the 
nonlesionaJ skin biopsy of the psoriatic patient (Fig SA) , demon-
stratiJ1g that TIG2 is highly expressed in uninvolved psoriatic skjn. 
In nonlesional skjn, TIG2 was expressed in basal and suprabasal 
layers of the epidermis, hair follicles, and endothelial cells. A 
reduction in TIG2 expression was observed in the psoriatic lesion 
compared to nonlesional skin (Fig SB) . TIG2 was strongly induced 
in psoriatic lesions after 3 or 14 d of tazarotene treatment (Fig 
SC,D). Hybridization of psoriatic lesional section with sense 
d.igoxigen.in-labeled TIG2 RNA probe rud not show srai.njng (Fig 
SE), thus demonstrating the speciftcity of TIG2 signal obtained 
w ith the anti-sense probe. 
The high expression of TIG2 message in uninvolved relative to 
lesional skin suggested that it may play a role in maintaining the 
normal physiology of skjn and tl1at of other tissues. Thus, various 
normal adult tissues were analyzed for TIG2 expression. Apart from 
skjn, TIG2 was also eJI.'Pressed in pancreas, liver, spleen, prostate, 
ovary, small intest:ll1e, and colon but not in heart, brain, placenta, 
lung, skeletal muscle, kjdney, thymus, testis , or peripheral blood 
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Figure 4. TIG2 is retinoid-inducible in a 3-dimensional culture 
system but not in 2-dimensional cnltures of keratittocytes and 
fibroblasts. Total RNA (10 p.g) from mock-treated (Control) or tazaro-
tene-treated keratinocytes (A), fibroblasts (B), and keratinocytes (C) cul-
tured in fibroblast-conditioned medium were subjected to northern blot 
hybridization. TIG2 and GAPDH sequences were detected with 32P-labeled 
eDNA probes prepared by random priming. The oven:llght Phosphorlmager 
exposmes of the blots are presented. (D) TIG2 expression is induced in an 
RAR-ligand-dependent marmer. Total RNA (10 p.g) from mock-treated 
(Control) , tazarotene-, SR11217-, SR11237- , or 1,25-dihydrO>.]'Vita.min 
0 3-treated skin raft cultures was subjected to northern blot hybridization. 
TIG2 and GAPDH sequences were detected with labeled eDNA probes. 
leukocytes (Fig 6), demonstrating the tissue-specific eli.'Pression of 
TIG2 in. llillo. GAPDH control of the multiple tissue northern blot 
is also shown. 
Chromosomal Localization of TIG2 BLAST search of TIG2 
eDNA sequence against luunan sequence tag site genornic clones 
database identified a clone (HSRSTS 367; GenBank accession 
number, Y07966) that displayed 100% nucleic acid homology over 
a stretch of 68 bp. The location of tlus STS clone fragment in the 
human genome maps the TIG2 gene to p13.3 region of chromo-
some 17. T herefore, TIG2 is located at 17p13.3 position . !J1terest-
ingly, this region is associated with pancreatic tumorigenesis (for 
references, see GenBank accession number Y07966). 
DISCUSSION 
In tlus manuscript, we describe the identification of TIG2, a n ew 
retinoid-responsive gene. TIG2 was isolated by a subtraction 
hybridization approach aimed at identifying genes regulated by 
tazarotene, an RAR/3/-y-selective anti-psoriatic synthetic retinoid. 
TIG2 is induced in a retinoid-dependent manner in skin rafts and in 
the epidermis of p sot;atic lesions (Fig 1, 5) . m contrast, it was 
neither expressed nor induced by retinoids in 2-dimensional cul-
tures of keratinocytes and fibroblasts (Fig 4). Thus, TIG2 is a 
muque retinoid-responsive gene in that it is retinoid-inducible only 
when keratinocytes and fibroblasts form a 3-dimensional tissue 
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structure as observed in skin rafts (Fig 1) and psoriatic lesions (Fig 
5). We also demonstrate that TIG2 expression is reduced in 
psoriatic lesions in comparison to nonlesional skin (Fig 5A,B), 
suggesting that its expression may play a role in maintaining the 
normal phenotype of the skin . TIG2 expression was significantly 
induced in llillo in psoriatic lesions after 3 d or 2 wk of topical 
application of tazarotene (Fig 5C,D). The early induction ofTIG2 
expression in the epidermis of the psodatic lesion after tazarotene 
treatment, along with the observation that TIG2 was induced in 
skin rafts in a retinoid-dependent manner, suggest that the TIG2 
induction is a result of direct effect of tazarotene on ke.ratinocyte 
gene expression rather than an overall tazarotene efi:ect on the 
lesional therapeutic status . Whether TIG2 is a marker of re tinoid 
efficacy in psoriasis can be determined only by elucidation of its 
biologic functions. 
TIG2 was induced only by RAR and not by RXR or VDR-
specific agonists (Fig 6) , although human keratinocytes contain 
E 
Figure 5. Retinoid-dependent induction of TIG2 in psoriatic le-
sions. In situ hybridization using cligox:igenin labeled anti-sense TIG2 RNA 
probes was perfonned in nonlesional psoriatic skin (A ) , Jesional psoriatic 
skin (B) , or lesional psoriatic skin after a 3-d (C) or 14-d (D) treatment with 
topical tazarotene gel (0.1%). In situ control with retinoid-treated psoriatic 
skin probed with digox:igenin-labeled sense TJG2 probe was also performed 
(E). Scale bar, 100 p.m. 
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TIG2-
GAPDH-
Figure 6. TIG2 is expressed iu various adult uormal hum au tissues. 
TIG2 expression was analyzed in multiple tissue northern blots (CLON-
TECJ-I, Pa lo Alto , CA) containing poly( A) + RNA from human heart, brain , 
placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, pros-
tate, testis, ovary, small intestine, colon, and peripheral blood leukocytes. 
tl-ese receptors in addition to R.ARs (Feldman eta/, 1980; Epstein 
and Bonifas, 1982; Fisher et al, 1994). Similarly, TIG1 was also 
responsive to RAR agonists aJld not to RXR or VDR Hgands 
(Nagpal eta/, 1996; unpubHshed observations) . It is also surprising 
that inspite of its re lative abundance in skin, RXRs are not able to 
transduce the signals of RXR-specific ligands in skin and other 
systems reported (Gendimenico et al, 1994; Sheikh et a/, 1994; 
Nagpal et al, 1996). RARs function i11 JJiJJo as RAR.- RXR het-
erodimers (Nagpal et a/, 1993), and it appears that for TTG2 
induction, only the occupation of the RAR ligand binding site of 
the heterodimer is required and that ligand binding to the R.XR site 
is ineffective. Altematively, the RXR ligand-binding site is not 
available for ligand binding as reported for RAR- RXR het-
erodimers on a DR.-5 DNA recognition motif (Kurokawa et al, 
1994). Further, the inactivity ofR.XR. ligands in TIG1 and TIG2 
induction (Nagpal et al, 1996; Fig. 6) suggests that the RXl~ 
homodimer pathway (Zha11g et a/, 1992) is silent in skin. 
CR.ABPIT is known to be an inducible marker of retinoid action 
in normal skin (Elder eta/, 1993), but it is expressed at a high level 
in psoriatic skin and cultured keratinocytes (Didierjea11 et al, 1991 ; 
Elder and Cromie, 1993). Further, its expression is inhibited by RA 
in cultured keratinocytes. These results suggest that in hyper-
proliferative or abnom1al differentiation states (as observed in psoriasis 
and cultured keratiJ1ocytes), another mechaJlism of CRABPIT regula-
tion is domli1ant over its regulation by retinoids. Therefore, our 
previously discovered retinoid responsive gene TIG1 (Nagpal et al, 
1996) and another novel gene TIG2 are the only genes known that are 
retinoid-inducible in psoriatic lesional skin. 
At present w e can only speculate about the function ofTIG2 a11d 
its role in RAR-mediated biology. The presence of an N-termli1al 
hydrophobic sequence (Fig 3A) suggests that TIG2 is a membrane-
associated protein. Therefore, TIG2 may play a role in cell-cell or 
cell-extracellular matrix interaction. The putative protein se-
quence ofTIG2 did not contaiJ1 calcium binding or hyaluronic acid 
binding motifs . The high level of TIG2 expression in uninvolved 
skll1 relative to lesional psoriatic skll1 suggests that TIG2 may play 
a role in the maintenance of the normal physiology of the skin. The 
presence of T!G2 in various normal tissues including the pancreas 
(Fig 6) and the association of its genetic locus (17p13.3) with 
pm1creatic tumorigenesis (see GenBank accession number Y07966) 
suggests that it may play a role i.J1 the nomul physiology of other 
organs as w ell. The actual physiologic fw1etions of TIG2 and the 
relevance of its up-regu lation to the therapeutic activity of tazaro-
tene in psoriasis should be addressed. The identification of retinoid-
responsive molecular markers, such as TIG1 and TIG2, in psoriatic 
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lesions are important first steps in understanding the m echanisms of 
retinoid action in psoriasis . 
We tlw11k S. Thacher a11d S. Fr·ia11t for ge11erously prouidi11g pri111ary foreskill 
kerati11ocytes aud fibroblasts. We also tlra11k Drs. L. VV/reeler a11d M . Roseutlwlefor 
nitica/ reuiew cif the ma1111script. j\!f.D. is supported by Gra11t. A R 399"15 (Nat io11al 
I11s titute cif Arthritis a11d Muswloskeletal a11d Skill Diseases) }i"o111 tire N ational 
l11stitutes of H ea/tl1. 
REFERENCES 
Boehm MF, Heyman RA, Patel S, Stein RB, N agpal S: Retinoids: biological function 
and usc in the treatment of dennatological diseases. Exp Opi11 In vest Dmgs 
4:593-61 2, 1995 
Boylan JF, G udas LJ: Overexpression of the ceUuJar retinoic acid-binding protein I 
(CRABP I) results in a reduction in differentiation-specifi c gene expression in F9 
teratocarcinoma cells. } Cell Biol112:965-979, 199 1 
Chambon P : The retinoid signalling pathways: molecular and genetic analyses . Sem h1 
Cefl Bioi 5:115-125, 1994 
Didierjean L, Durand B, Saurat J-H: Cellular rctinoic acid-binding protein type 2 
mR..NA is overexpressed in human psoriatic skin as shown by ill situ hybridization . 
Biocltem Biopltys R es Commuu 180:204 - 208, 1991 
Elder JT, Cromie MA: Retinoid regulation of CR.AB P- !1 m.RNA in an organotypic 
keratinocytc culture system. j Toxicol Cutarreous Owl To~·icol12:173-t81, 1993 
Elder JT, C romie MA. Griffiths CEM . Cham bon P, Voorhees JJ: Stimu.lus-selective 
induction ofCRABP-11 mll...NA: a marker for retinoid acid action in Iutman skin . 
J lu vesc Denuatol100:356-359, 1993 
Epstein EH Jr. Bonifas JM: Glucocorticoid receptors of nonnal human epjdcm1is . 
j lrwest Dermalol78:144-146, 1982 
Esgleyes-Ribot T, Chandraratna RAS , Lew-Kaya DA, SeftonJ , Ouvic M: Response of 
psorias.is to a new topical retinoid, AGN 1901 68. ) A 111 A cad O erlllatol 30:581-590, 
1.994 
Feldman 0, C hen T , Hirst M . Colston K, Karasek M, Cone C: Demonstration of 
1 ,25-dihydroxy vitamin D 3 receptors in hum;m skiJ1 bjopsies. J C/iu E udocriuol 
Metab 51:1463-1465, 1980 
Fiorella PO, N apoli JL: Expression of cellular retinoic acid-binding protein (CRABP) 
in Escherichia coli.) Bioi C lrem 266:16572-1 6579, 1991 
Fisher GJ, Talwar HS , Xiao J-H, Datta SC, Reddy AP, Gaub M-P, Rochette-Egly C , 
C bambon P, Voothces JJ: lnununo loglcal identification and functional quantita-
tio n of retinoic acid and retinoid X receptor proteins in human skin. J Bioi Cl1em 
269:20629-20635, 1994 
Gcndimenico GJ, Stim TB , Corbo M , Janssen B, MezickJA: A pleiotropic response is 
induced in F9 embryonal carcinoma cells and rhino mouse skin by all-trans-
retiuoic acid, a R.AR agonist but not by SRI1237, a RXR-selective agonis t. 
j ltrvesc Denuatol l 02:676 - 680, 1994 
Krueger GG , Duvic M: Epidemiology of psoriasis: clinical issues . J luvest DL>Jlllntol 
102:14S-1 8S, 1994 
Kurokawa 11.., DiRenzo J , Boehm M. Sugannan J , Gloss B, Rosenfeld MG, Heyman 
RA, Glass CK: Regulation of retinoid sib'llalling by receptor po larity and 
allosteric control of ligand binding. Nature 371:528-531, 1994 
Lehmann JM, Jong L, Fanjul A, Cam eron JF, Lu X I', HaeJi1er P, Dawson, Pf.1hl M: 
.R.etinoids selective for retinoid X receptor response pathways. Sc.icucc 258:1944-
1946, 1992 
Li W-B. Gruber CE, Lin J-J, Lim R , D 'AJessio JM, Jessee JA: The isolation of 
dilferentially expressed genes in fibroblast gro wth f.1ctor stirnu.la ted BC3H1 cells 
by subtractive hybridization. BioTeclmiques 16:722- 729. I 994 
Mangclsdorf DJ, Umesono K, Evans. RM: The retinoid receptors. In : Sporn MB. 
R oberts A.B, Goodman OS (eds.). The Retinoicls: Biology, C hemiscr]'• aud M ediciue. 
Raven Press, New York, pp 319-349, 1994 
Nagpal S, Atbani.kar J, Chandraratna RAS: Separation of transactivat:ion and AP1 
antagonism functions of rctinoic add receptor o:.j Bioi C ltem 270:923-927, 1995 
Nagpal S, C handraratna R.AS: R .. cti.noids as a.nti-cauccr agents. C 111T Pltnnunccutical 
De.s(~u 2:295-316. 1996 
Nagpal S, Friant S. N akshatri H, C hambon P: RA.Rs and R.A'Rs: evidence for two 
autonomous transactivation functions (AF-1 and AF-2) and heterodimcrizacion iu 
vivo. EMBO J 12:2349 - 2360, 1993 
Nagpal S, Patel S, Asano AT.Johnson AT, Duvic M , C handra.ratna RAS: Tazarotene-
induced gene 1 (TIG 1), a novel re tinoic acid receptor-responsive gene in slcin. 
J Irwesl Derw acol106:269 -274, 1996 
Nagpal S, Saunders M., Kastner P, Durand B, Nakshatri H, C hambo n P: Promoter 
context- and response c lement-dependent specificity of the transcriptional activa-
tion :md modulating functions of retinoic add receptors. Celf 70:1007-1019, 1992 
Peck GJ , DiGiovanna JJ : Synthetic retiuoids in dennatology. ln : Sporn MB, Roberts 
A.B, Goodman DS (eds.). TIJC R etilwids: Biology, Chemist')'~ nud i\4ediciue. Raven 
Press, New York, pp 631-638 1994 
Sheikh MS. Shao Z-M, Li X-S, Dawson M, Jctten AM, Wu S, Conley BA. Garcia M . 
Rochefort 1-l , Fontana JA: Retinoid-resistant estTogen receptor-negative human 
breast carcinoma cells tnm sfected \vid1 retinok acid receptor-a acquire scnsjtiviry 
to growth inhibition by retinoids. J Bioi C lwm 269:2"1440-21447, 1994 
Weinstein GO: Safety, efficacy and duration of therapeutic elfect oftazarotene used in 
the treatment of plaque psoriasis. Brj Demracol135(suppl 49) :32- 36, 1996 
Z han g X, Lehmatut J, H offiu::m.n B, Dawson Ml , Cameron J , Graupner G , Hermam1 
T, Tran 1', Pf.1hl M: Ho modimer formation of retinoid X recepto r induced by 
9-cis-retinoic acid . Nacurc 358:587-591, 1992 
